NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Novo Nordisk ( NVO 1.82%) stock jumped 3% through 10:55 a.m. Tuesday on some potentially positive news in the GLP-1 weight ...

That’s a bit harsh given Denmark’s strong growth compared with neighboring countries over the past few years has been largely ...

Regional equity markets closed in positive territory on Tuesday, building positive momentum after a muted trading session on Monday.

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Novo Nordisk announced on Friday morning that its CEO Lars Fruergaard Jørgensen is stepping down after leading the company for eight years. In a release announcing the decision, the Danish pharma ...

HONG KONG — Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign ...